PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33473169-2	2021	The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer.	Lapatinib	38-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116